MRHFM and the FDA Support Personalized Medicine for Mesothelioma
St. Louis, MO (PRWEB) January 17, 2014 -- Also called “individualized” or “customized” medicine, personalized medicine is an innovative subcategory of medicine that the FDA has recognized as topic of focus for treating diseases such as mesothelioma cancer. According to Harvard Medical School’s Partners Healthcare Center for Personalized Genetic Medicine (PCPGM), personalized medicine is the ability to determine an individual's unique molecular characteristics and to use those genetic distinctions to:
• Diagnose more finely an individual's disease
• Reduce possible adverse reactions
• Select treatments that increase the chances of a successful outcome
“Individualized diagnosis, treatment, and prevention are crucial to the fight against mesothelioma and other types of cancers,” said Neil Maune, partner at MRHFM. “With the FDA’s support, we hope that more funding and wide-spread information about personalized medicine for patients will be accessible in the United States.”
In a 61-page report titled "Paving the Way for Personalized Medicine: FDA's Role" that was published on the FDA’s website in October 2013, the organization states that it plans to help further personalized medicine by focusing on advanced regulatory science. Thanks to this commitment, a number of breakthroughs in genetic research have made it possible for researchers to target specific genetic mutations, which will help lead them to new and more effective mesothelioma treatments. While a traditional approach to mesothelioma treatment may very well be effective in some cases, researchers say that if treatment is more individualized based on the patient’s unique, specific traits, it will fulfill its purpose to better diagnose an individual's disease, reduce adverse reactions, and increase the chances of a positive outcome following treatment. You can find more information on mesothelioma treatment options at http://www.mesotheliomabook.com.
This individual approach to treatment will also minimize or eliminate the need to participate in experimental treatments and ease patient fears based on the idea that a personalized treatment path offers more promise than a one-size-fits-all approach to treating mesothelioma.
The law firm of MRHFM focuses exclusively on mesothelioma cases and works to educate the public about the mesothelioma industry and advancements in treatment for mesothelioma cancer. The law firm advocates for mesothelioma research also offers a free book about mesothelioma titled “100 Questions & Answers About Mesothelioma” that is available for request online at http://www.mesotheliomabook.com.
About Maune Raichle Hartley French & Mudd, LLC
Maune Raichle Hartley French & Mudd, LLC is a mesothelioma law firm based in St. Louis, MO. With offices across the country, their size and exclusive focus on mesothelioma cases allows them to represent clients through the process as quickly as possible and maximize their clients’ recovery. The attorneys at MRHFM have represented thousands of victims exposed to asbestos. The firm has 29 attorneys across the country, 16 investigators, 7 client service managers, and additional support staff including paralegals and legal assistants. For more information about Maune Raichle Hartley French & Mudd, LLC, visit http://www.mesotheliomabook.com.
James J. Caruso, MRHFM, http://www.mesotheliomabook.com, +1 (866) 234-7997, [email protected]
Share this article